Aronex Pharmaceuticals' CEO Geoffrey Cox talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Oct.3, 2000 The Wall Street Transcript has published an in-depth interview with Geoffrey Cox (Charles) Geoffrey Cox, QC (born April 30, 1960) is a British Conservative politician and barrister. He is the Member of Parliament for Torridge and West Devon. Geoffrey Cox was educated at King's College, Taunton and Downing College, Cambridge. , CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Aronex Pharmaceuticals (Nasdaq:ARNX), in which he talks at length about the company's future. The entire 2,100-word interview is available free online at http://www.twst.com/ceos.htm Cox gives an overview of the company. "We started in 1986 and went public in 1992. The company is not a basic-discovery company -- it's a product-development company. It focuses on taking potential pharmaceutical products through the development process into the commercial arena. The focus of the company is on cancer and infectious diseases infectious diseases: see communicable diseases. . We have four products in development, two of which are in an advanced stage, including one product that is presently under review by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for approval." Cox explains, "It is important for us to execute on our programs and move through the regulatory process. No matter how big or small the company, no matter how good you think your product is, pushing drug candidates through the regulatory process is always a challenge associated with a great deal of uncertainty. I think a very important defining issue in terms of companies making the transition from being development stage into full operating companies operating company A business that engages in transactions with outsiders. is defined by their success in the regulatory process." Looking forward, Cox states, "What we're seeing now is a much greater fundamental understanding of the basis of disease from a genetic perspective and a better understanding of the biochemistry and of how diseases develop. In our area of oncology, this understanding is going to be very helpful in terms of developing drugs, which are much more precise and much more targeted to the particular disease areas." This interview is part of a 288-page UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control Global Life Sciences Conference Issue available at http://www.twst.com/info/info181.htm or by calling (212) 952-7433 The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors Long-term investor A person who makes investments for a period of at least five years in order to finance his or her long-term goals. for over 37 years. The Wall Street Transcript has launched a new free service where investors can ask Aronex Pharmaceuticals (or any public company) a question at http://www.qawire.com The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call (800) 246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion